1. Search Result
Search Result
Results for "

OA

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

11

Natural
Products

12

Recombinant Proteins

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121936

    Drug Derivative Cardiovascular Disease Inflammation/Immunology
    Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA) .
    Yohimbic acid
  • HY-121936A

    Drug Derivative Cardiovascular Disease Inflammation/Immunology
    Yohimbic acid hydrate is an amphoteric demethylated derivative of Yohimbine (HY-12715). Yohimbic acid hydrate exhibits vasodilatory action. Yohimbic acid hydrate also can be used for the research of osteoarthritis (OA) .
    Yohimbic acid hydrate
  • HY-N0665
    Specnuezhenide
    1 Publications Verification

    (8E)-Nuezhenide

    NF-κB Wnt Inflammation/Immunology
    Specnuezhenide ((8E)-Nuezhenide) is isolated from the fruits of?Ligustrum lucidum. Specnuezhenide ((8E)-Nuezhenide) can inhibit IL-1β-induced inflammation in chondrocytes via inhibition of NF-κB and wnt/β-catenin signaling. Specnuezhenide ((8E)-Nuezhenide) exerts anti-inflammatory effects in a rat model of osteoarthritis (OA) .
    Specnuezhenide
  • HY-B2082

    VEGFR Ferroportin NF-κB Mitochondrial Metabolism Neurological Disease Inflammation/Immunology Cancer
    Fursultiamine is a vitamin B1 derivative, has anti-nociceptive and antineoplastic activity. Fursultiamine is the antagonist for hepcidin, that inhibits the binding of hepcidin to the iron efflux protein Ferroportin (FPN1), thereby promoting the efflux of intracellular iron. Fursultiamine is also the inhibitor for NF-κB signaling pathway. Fursultiamine can be used for vitamin B1 deficiency, osteoarthritis (OA) and cancer research .
    Fursultiamine
  • HY-N0866
    20-Deoxyingenol
    3 Publications Verification

    Autophagy Inflammation/Immunology
    20-Deoxyingenol, a diterpene, is isolated from the roots of Euphorbia kansui. 20-Deoxyingenol can promote autophagy and lysosomal biogenesis by promoting the nuclear translocation of transcription factor EB (TFEB) in vitro. 20-Deoxyingenol can be used for the research of osteoarthritis (OA) .
    20-Deoxyingenol
  • HY-P2414

    MMP Inflammation/Immunology
    MMP-13 Substrate is a substrate of MMP-13. MMP-13 Substrate can be used for the research of osteoarthritis (OA) .
    MMP-13 Substrate
  • HY-P2414A

    MMP Inflammation/Immunology
    MMP-13 Substrate TFA is a substrate of MMP-13. MMP-13 Substrate TFA can be used for the research of osteoarthritis (OA) .
    MMP-13 Substrate TFA
  • HY-W746555S

    Metazachlor OA-d9; Metazachlor oxalic acid-d9

    Isotope-Labeled Compounds Others
    Metazachlor metabolite BH479-4-d9 (Metazachlor OA-d9) is deuterium labeled Metazachlor Oxalic Acid .
    Metazachlor metabolite BH479-4-d9
  • HY-W714203S

    2-(Isopropyl(phenyl)amino)-2-oxOAcetic acid-d5

    Isotope-Labeled Compounds Others
    Propachlor OA-d5 (2-(Isopropyl(phenyl)amino)-2-oxoacetic acid-d5) is deuterium labeled 2-(Isopropyl(phenyl)amino)-2-oxoacetic acid .
    Propachlor OA-d5
  • HY-N0665R

    NF-κB Wnt Inflammation/Immunology
    Specnuezhenide (Standard) is the analytical standard of Specnuezhenide. This product is intended for research and analytical applications. Specnuezhenide ((8E)-Nuezhenide) is isolated from the fruits of?Ligustrum lucidum. Specnuezhenide ((8E)-Nuezhenide) can inhibit IL-1β-induced inflammation in chondrocytes via inhibition of NF-κB and wnt/β-catenin signaling. Specnuezhenide ((8E)-Nuezhenide) exerts anti-inflammatory effects in a rat model of osteoarthritis (OA) .
    Specnuezhenide (Standard)
  • HY-16268
    Kartogenin
    Maximum Cited Publications
    23 Publications Verification

    KGN

    TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
    Kartogenin
  • HY-112546

    MMP Cancer
    MMP-2 Inhibitor I (OA-Hy) is a potent MMP-2 inhibitor with a Ki of 1.7 μM .
    MMP-2 Inhibitor I
  • HY-146981

    Glycosidase Inflammation/Immunology
    α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivativ eagainst α-glucosidase(IC50=0.35 µM) and α-amylase.
    α-Glucosidase-IN-3
  • HY-129467

    2-Hydroxyoleic acid; 2-OHOA; LAM561

    Apoptosis Cancer
    (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect .
    (Rac)-Idroxioleic acid
  • HY-129467A

    2-Hydroxyoleic acid sodium; 2-OHOA sodium; LAM561 sodium

    Apoptosis Cancer
    (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) sodium is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid sodium has anti-tumor effect .
    (Rac)-Idroxioleic acid sodium
  • HY-P99195

    Trk Receptor Inflammation/Immunology
    Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
    Fasinumab
  • HY-149377

    MMP Metabolic Disease
    MMP13-IN-4 (compound 13) is a potent and selective inhibitor of MMP-13 (IC50=14.6 μM),involved in osteoarthritis (OA) .
    MMP13-IN-4
  • HY-P99627

    NV-02

    Trk Receptor Inflammation/Immunology
    Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .
    Frunevetmab
  • HY-146984

    Glycosidase Inflammation/Immunology
    α-Glucosidase-IN-3 is an oleanolic acid (OA) oxime ester derivative against α-glucosidase (IC50=1.28 µM) and α-amylase (IC50=3.8 µM) .
    α-Amylase-IN-2
  • HY-125415

    PGE synthase Inflammation/Immunology
    PF-4693627 is a potent, selective and orally bioavailable microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor (IC50=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA) .
    PF-4693627
  • HY-151524

    Cathepsin Inflammation/Immunology
    Cathepsin K inhibitor 3 (compound 23) is a highly selective cathepsin K inhibitor with an IC50 value of 0.5 nM. Cathepsin K inhibitor 3 has a favorable pharmacokinetic profile and may be used in osteoarthritis (OA) disease studies .
    Cathepsin K inhibitor 3
  • HY-160822

    PF-5212371

    ADAMTS Inflammation/Immunology
    AGG-523 (PF-5212371) is a reversible, non-hydroxamate, zinc-binding selective aggrecanase 1 (ADAMTS4) and aggrecanase 2 (ADAMTS5) inhibitor. AGG-523 can be used for the study of osteoarthritis (OA) .
    AGG-523
  • HY-169949

    MAP3K Inflammation/Immunology
    TAK-756 is a TAK1 inhibitor with good selectivity for IRAK1/4 and excellent intra-articular pharmacokinetic properties. TAK1 is a potential molecular target for osteoarthritis (OA) with complementary anti-catabolic and anti-inflammatory effects .
    TAK-756
  • HY-149378

    MMP Metabolic Disease
    MMP13-IN-5 (compound 13m) is a potent and selective inhibitor of MMP-2/MMP-13 (IC50=3.6 μM/14.6 μM),involved in osteoarthritis (OA) .
    MMP13-IN-5
  • HY-W016819B

    5-Fluorouracil-6-carboxylic acid Mono(hydrate); 5-FOA; 5-fluoro OA

    Others Infection
    5-Fluoroorotic acid (monohydrate) (5-Fluorouracil-6-carboxylic acid Mono(hydrate); 5-FOA) is used to detect URA3 gene expression in yeast molecular genetic constructs. Yeast with an active URA3 gene (which encodes orotidine-5'-monophosphate decarboxylase) convert 5-FOA to fluorodeoxyuridine, which is toxic to cells. Resistant yeast strains carrying mutations in the URA3 gene will grow in the presence of 5-FOA if uracil is added to the culture medium.
    5-Fluoroorotic acid monohydrate
  • HY-162514

    Epigenetic Reader Domain Inflammation/Immunology
    BBC0403 is a selective BRD2 inhibitor with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. BBC0403 exhibitS higher binding specificity for BRD2 compared to BRD3 and BRD4. BBC0403 has the potential for osteoarthritis (OA) research .
    BBC0403
  • HY-100359
    CL-82198
    5 Publications Verification

    MMP Inflammation/Immunology Cancer
    CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs . CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression .
    CL-82198
  • HY-13507

    COX-189

    COX Metabolic Disease Inflammation/Immunology Cancer
    Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06?μM . Lumiracoxib acts as a nonselective NSAID with?anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
    Lumiracoxib
  • HY-13507R

    COX Metabolic Disease Inflammation/Immunology Cancer
    Lumiracoxib (Standard) is the analytical standard of Lumiracoxib. This product is intended for research and analytical applications. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM . Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
    Lumiracoxib (Standard)
  • HY-N0801

    MMP Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    Polygalacic acid, is a triterpene, isolated from the root of Polygala tenuifolia Willd. Polygalacic acid inhibits MMP expression. Polygalacic acid may have a therapeutic effect in Osteoarthritis (OA) treatment . Polygalacic acid exerts a significant neuroprotective effect on cognitive impairment, PA improves cholinergic system reactivity by inhibiting acetylcholinesterase (AChE) activity, increasing choline acetyltransferase (ChAT) activity, and elevating levels of acetylcholine (Ach) in the hippocampus and frontal cortex .
    Polygalacic acid
  • HY-N8060A

    Orotidine monophosphate trisodium; Orotidylic acid trisodium

    Endogenous Metabolite DNA/RNA Synthesis Metabolic Disease
    Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT) .
    Orotidine 5′-monophosphate trisodium
  • HY-N1584
    Halofuginone
    10+ Cited Publications

    RU-19110

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone
  • HY-N1584C
    Halofuginone lactate
    10+ Cited Publications

    RU-19110 lactate

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone lactate
  • HY-N1584A
    Halofuginone hydrobromide
    10+ Cited Publications

    RU-19110 hydrobromide

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrobromide
  • HY-108672

    P2Y Receptor Inflammation/Immunology
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) .
    NF157
  • HY-N1584B

    RU-19110 hydrochloride

    Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrochloride
  • HY-N1584R

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (Standard) is the analytical standard of Halofuginone. This product is intended for research and analytical applications. Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone (Standard)
  • HY-122624

    MMP Inflammation/Immunology
    MMP13-IN-2 is a potent, selective and orally active MMP-13 inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC50=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research .
    MMP13-IN-2
  • HY-161953

    OGA Neurological Disease
    O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects .
    O-GlcNAcase-IN-2
  • HY-N1584BR

    Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (hydrochloride) (Standard) is the analytical standard of Halofuginone (hydrochloride). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects [4] .
    Halofuginone (hydrochloride) (Standard)
  • HY-N1584AR

    DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone (hydrobromide) (Standard)
  • HY-16268A
    Kartogenin sodium
    Maximum Cited Publications
    23 Publications Verification

    KGN sodium

    TGF-beta/Smad Inflammation/Immunology
    Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
    Kartogenin sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: